Immuron Limited · ASX:IMC
Immuron — MarketOpen Direct Connect Webinar (August 2024)
18 slides from Immuron's conference presentation, Aug 9, 2024
Slide 1: Direct Connect Webinar
8 AUGUST 2024 Steven Lydeamore Chief Executive Officer Direct Connect Webinar NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” ” intends,” ” plans,” ” believes,” ” seeks,” “estimates,” “guidance” and s imilar expressions are intended
Slide 3: Executive summary
3 Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases 3 as of 6 August 2024 recruited ~77% of target 866 CampETEC Phase 2 clinical trial
Slide 4: Addressable market & industry overview
4 Chief Commercial Officer has 20+ year’s experience with local and global (Asia, UK) commercial leadership roles with GSK and P&G Addressable market & industry overview * IMC Company Report - Travelan Market Analysis 2019 ** Centers for Disease Control and Prevention Yellow Book USA Market FY24: la
Slide 5: Technology platform
5 + Reduce occurrence and reduce/relieve diarrhoea + Reduce/relieve abdominal cramping + Reduce/relieve gastrointestinal pain + Assists repair of gastrointestinal/gut wall lining + Enhance/promote immune defence + Enhance/promote health liver function Australian Permitted indications; these statemen
Slide 6: Travelan mechanism of action
6 Pre - Clinical Studies Broad spectrum antimicrobial Travelan® | Mechanism of action With Travelan ® Bacteria neutralized by Travelan ® antibodies Without Travelan® Bacteria attach to gut wall and infect Protects against bacterial adhesion to host cell intestinal epithelia Binds to surface layer pr
Slide 7: IMM-124E (Travelan) Phase 2 Study additional data analysis: Protective Efficacy
7 Further analysis of the Phase 2 Study found that some subjects did not experience any diarrhoea until after antibiotics were administered Diarrhoea could be related to antibiotic administration Protective Efficacy was calculated for the 5 - day period post challenge There were 4 subjects i
Slide 8: Subjects with diarrhea of any severity
8 SUBJECTS WITH DIARRHEA OF ANY SEVERITY Placebo (N=30) Travelan® (N=30) Intent - to - treat Analysis Set 16 (53.3%) 13 (43.3%) Number of subjects with ETEC - induced diarrhoea of any severity [1] 0.438 P - value ( - 15.2%, 35.2%) 95% 2 - sided Confidence Interval Placebo (N=30) Travelan® (N=30) PE
Slide 9: IMM-124E (Travelan): Kaplan-Meier Plot
9 Objective : To compare the time to diarrhoea onset between patients receiving a therapeutic treatment and those receiving a placebo. Data Collection : o Patients are monitored over a specified period. o The time to the onset of diarrhoea is recorded for each patient. o Patients are divided into tw
Slide 10: Time to diarrhoea onset
10 TIME TO DIARRHOEA ONSET Time to Diarrhea onset • The Kaplan - Meier estimator is useful for determining the time of the onset of diarrhoea between patients receiving Travelan® or placebo treatment • Y - Axis : Probability of remaining diarrhoea - free • X - Axis : Time to onset of diarrhoea • The
Slide 11: Phase 2 Study additional data analysis: Adverse Events
11 Includes all safety data set (63 subjects) and additional 3 subjects who were not challenged Considers all Adverse Events and number of events over the whole study period pre and post challenge Number of events is reduced in the Travelan® treated group for all organ classes IMM - 124E (Trav
Slide 12: Summary of adverse events
12 SUMMARY OF ADVERSE EVENTS Reduction in number of Events % Placebo (N=31) Travelan (N=32) Subjects with at least 1 AE per System organ class Includes all safety data set (63 subjects) Events (m) Subjects n Events (m) Subjects n 46.8% 109 28 (90.3%) 58 24 (75%) Total 34.9% 66 28 43 23 Gastrointesti
Slide 13: Summary of Enrolled Participants and Demographics
13 IMM - 124E (Travelan®) Phase 2 Study – additional data analysis Summary of Enrolled Participants and Demographics
Slide 14: All enrolled subjects
14 ALL ENROLLED SUBJECTS Total (N=63) Placebo (N=31) Travelan® (N=32) 63 31 32 Randomization Included in 63 31 32 Safety Analysis Set 60 30 30 Intent - to - Treat Analysis Set 54 27 27 Completed Study 9 4 5 Discontinued Study 6 3 3 Subject Withdrew Consent 2 0 2 Investigator Discretion 1 1 0 Lost to
Slide 15: Demographics
15 DEMOGRAPHICS Total (N=63) Placebo (N=31) Travelan® (N=32) 34.1 35.1 33.1 Mean Age at Consent Sex at Birth 34 16 18 Male 29 15 14 Female Ethnicity 15 10 5 Hispanic/Latino 48 21 27 Not Hispanic/Latino Race 13 (20.6%) 5 (16.1%) 8 (25%) White 45 (71.4%) 22 (71%) 23 (71.9%) Black or African American 1
Slide 16: IMM-124E Phase 3 strategy
16 IMM - 124E Phase 3 strategy Phase 1 clinical study (Baltimore, 1996) Phase 2 clinical study (Poland, 2000) FDA 1 IND 2 approval (December 2022) Phase 2 clinical study (Baltimore, 2024) Additional topline data analysis August 2024 Clinical Study Report anticipated September 2024 End of Phase 2 FDA
Slide 17: Contact information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 18: Scientific references
18 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy
Immuron — MarketOpen Direct Connect Webinar (August 2024) on 6ix